GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerative Medical Technology Group Inc (OTCPK:RMTG) » Definitions » Revenue

RMTG (Regenerative Medical Technology Group) Revenue : $3.21 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Regenerative Medical Technology Group Revenue?

Regenerative Medical Technology Group's revenue for the three months ended in Sep. 2024 was $0.99 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $3.21 Mil. Regenerative Medical Technology Group's Revenue per Share for the three months ended in Sep. 2024 was $0.08. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.26.

Warning Sign:

Regenerative Medical Technology Group Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Regenerative Medical Technology Group was 34.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 218.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 103.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Regenerative Medical Technology Group's highest 3-Year average Revenue per Share Growth Rate was 218.60% per year. The lowest was -9.10% per year. And the median was 111.00% per year.


Regenerative Medical Technology Group Revenue Historical Data

The historical data trend for Regenerative Medical Technology Group's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerative Medical Technology Group Revenue Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 0.03 0.06 0.44 1.53 2.41

Regenerative Medical Technology Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.62 0.82 0.79 0.99

Competitive Comparison of Regenerative Medical Technology Group's Revenue

For the Biotechnology subindustry, Regenerative Medical Technology Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerative Medical Technology Group's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's Revenue distribution charts can be found below:

* The bar in red indicates where Regenerative Medical Technology Group's Revenue falls into.



Regenerative Medical Technology Group Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenerative Medical Technology Group  (OTCPK:RMTG) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Regenerative Medical Technology Group Revenue Related Terms

Thank you for viewing the detailed overview of Regenerative Medical Technology Group's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerative Medical Technology Group Business Description

Traded in Other Exchanges
N/A
Address
433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc operates through its subsidiary. Its focus has been mainly dedicated to its operations serving the markets in the regenerative medicine industry. It believes stem cell therapy is becoming an increasingly effective clinical solution for treating conditions that traditional or conventional medicine only offers within palliative care and pain management. Patients around the world are seeking a natural regenerative alternative without the potential risks and side effects sometimes associated with conventional pharmaceuticals.
Executives
Benito Novas 10 percent owner 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
David Eugene Christensen director, 10 percent owner, officer: President and CEO 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Pereira Melvin Antonio Loria director, 10 percent owner, officer: CEO, Chairman RESIDENCIAL HACIENDA EL GREGAL, #24-1 SANCHEZ, CURRIDABAT, SAN JOSE G2 11803